Ftse Mib
34.542,01
0,00%
DAX
18.494,89
-0,33%
S&P 500
5.360,79
0,26%
NASDAQ
17.192,53
0,35%
Bitcoin
67.713,39
-2,58%
Registration Strip Icon for charts Registrati per grafici in tempo reale, strumenti di analisi e prezzi.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Brooklyn ImmunoTherapeutics Inc (BTX) Brooklyn ImmunoTherapeutics Inc (BTX) Notizie

BTX

Brooklyn ImmunoTherapeut... (BTX)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:BTX
DataOraFonteTitoloSimboloCompagnia
11/05/202322:35Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:BTXBrooklyn ImmunoTherapeutics Inc
10/05/202312:02Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:BTXBrooklyn ImmunoTherapeutics Inc
05/05/202313:02Edgar (US Regulatory)Annual Report to Security Holders (ars)NASDAQ:BTXBrooklyn ImmunoTherapeutics Inc
05/05/202313:01Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:BTXBrooklyn ImmunoTherapeutics Inc
05/05/202312:31Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:BTXBrooklyn ImmunoTherapeutics Inc
25/04/202315:02Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(3) (424b3)NASDAQ:BTXBrooklyn ImmunoTherapeutics Inc
20/04/202322:31Edgar (US Regulatory)Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a)NASDAQ:BTXBrooklyn ImmunoTherapeutics Inc
04/04/202323:15Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:BTXBrooklyn ImmunoTherapeutics Inc
04/04/202323:05Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:BTXBrooklyn ImmunoTherapeutics Inc
20/12/202222:31Edgar (US Regulatory)Statement of Beneficial Ownership (sc 13d)NASDAQ:BTXBrooklyn ImmunoTherapeutics Inc
16/12/202223:01Edgar (US Regulatory)Small Company Offering and Sale of Securities Without Registration (d)NASDAQ:BTXBrooklyn ImmunoTherapeutics Inc
14/12/202222:31Edgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)NASDAQ:BTXBrooklyn ImmunoTherapeutics Inc
07/12/202200:52Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:BTXBrooklyn ImmunoTherapeutics Inc
02/12/202223:01Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:BTXBrooklyn ImmunoTherapeutics Inc
11/10/202214:30GlobeNewswire Inc.Brooklyn ImmunoTherapeutics Announces Name Change to Eterna Therapeutics and Provides Corporate UpdatesNASDAQ:BTXBrooklyn ImmunoTherapeutics Inc
26/07/202213:30GlobeNewswire Inc.Brooklyn ImmunoTherapeutics Announces Results of Phase 2 Study of IRX-2 in Head and Neck CancerNASDAQ:BTXBrooklyn ImmunoTherapeutics Inc
17/06/202223:00GlobeNewswire Inc.Brooklyn ImmunoTherapeutics Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price DeficiencyNASDAQ:BTXBrooklyn ImmunoTherapeutics Inc
07/06/202213:30GlobeNewswire Inc.Brooklyn ImmunoTherapeutics Announces Board ChangesNASDAQ:BTXBrooklyn ImmunoTherapeutics Inc
31/05/202213:30GlobeNewswire Inc.Brooklyn ImmunoTherapeutics Announces Changes to Executive Management: Matt Angel, Ph.D. Appointed Interim Chief Executive Officer and President, Andrew Jackson Appointed Chief Financial Officer Postpones 2022 Annual MeetingNASDAQ:BTXBrooklyn ImmunoTherapeutics Inc
27/05/202222:30GlobeNewswire Inc.Brooklyn ImmunoTherapeutics Announces Receipt of Notice from Nasdaq Regarding Delayed Filing of Quarterly Report on Form 10-QNASDAQ:BTXBrooklyn ImmunoTherapeutics Inc
19/05/202214:23GlobeNewswire Inc.Amarin Announces Appointment of New Directors and Board Leadership ChangesNASDAQ:BTXBrooklyn ImmunoTherapeutics Inc
29/04/202222:35Edgar (US Regulatory)Securities Registration Statement (simplified Form) (s-3)NASDAQ:BTXBrooklyn ImmunoTherapeutics Inc
21/04/202213:30GlobeNewswire Inc.Brooklyn ImmunoTherapeutics Announces Establishment of New Research and Development Facility for Advancement of Engineered Cellular MedicinesNASDAQ:BTXBrooklyn ImmunoTherapeutics Inc
15/04/202223:10Edgar (US Regulatory)Annual Report (10-k)NASDAQ:BTXBrooklyn ImmunoTherapeutics Inc
15/04/202222:15GlobeNewswire Inc.Brooklyn ImmunoTherapeutics Announces Fourth Quarter and Full Year 2021 Financial ResultsNASDAQ:BTXBrooklyn ImmunoTherapeutics Inc
01/04/202212:31Edgar (US Regulatory)Notification That Annual Report Will Be Submitted Late (nt 10-k)NASDAQ:BTXBrooklyn ImmunoTherapeutics Inc
09/03/202222:15GlobeNewswire Inc.Brooklyn ImmunoTherapeutics Announces Closing of $12 Million Private PlacementNASDAQ:BTXBrooklyn ImmunoTherapeutics Inc
07/03/202214:00GlobeNewswire Inc.Brooklyn ImmunoTherapeutics Announces $12 Million Private PlacementNASDAQ:BTXBrooklyn ImmunoTherapeutics Inc
20/01/202213:30GlobeNewswire Inc.Brooklyn ImmunoTherapeutics Welcomes Erin S. Enright and Heather B. Redman to Its Board of DirectorsNASDAQ:BTXBrooklyn ImmunoTherapeutics Inc
13/01/202214:30GlobeNewswire Inc.Brooklyn ImmunoTherapeutics Provides Update on Regenerative Medicine Intellectual Property PortfolioNASDAQ:BTXBrooklyn ImmunoTherapeutics Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:BTX

La tua Cronologia

AQSE
HOGS.GB
WisdomTree Commodity Sec...
BIT
P18UH8
BNP Paribas Issuance
BIT
P1S302
NLBNPIT1S302 20240621 320
BIT
P1S0K0
NLBNPIT1S0K0 20241220 0.25
BIT
P1Z3P4
NLBNPIT1Z3P4 20991231 86...
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network